Cover Image
市場調查報告書

甲狀腺疾病治療的全球市場 (甲狀腺機能低下症及甲狀腺功能亢進症) - 產業分析、規模、構成比、成長率、趨勢及預測:2015-2023年

Thyroid Gland Disorders Treatment Market (Disorders - Hypothyroidism (Levothyroxine and Liothyronine) and Hyperthyroidism (Imidazole and Propacil)) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2017 - 2025

出版商 Transparency Market Research 商品編碼 345766
出版日期 內容資訊 英文 173 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
甲狀腺疾病治療的全球市場 (甲狀腺機能低下症及甲狀腺功能亢進症) - 產業分析、規模、構成比、成長率、趨勢及預測:2015-2023年 Thyroid Gland Disorders Treatment Market (Disorders - Hypothyroidism (Levothyroxine and Liothyronine) and Hyperthyroidism (Imidazole and Propacil)) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2017 - 2025
出版日期: 2018年02月13日 內容資訊: 英文 173 Pages
簡介

甲狀腺是由甲狀腺細胞形成,從食物吸收碘轉換成三碘甲腺胺酸 (T3) 和甲狀腺素 (T4) 。這些荷爾蒙放出到血流中,發揮控制代謝的重要作用。甲狀腺疾病定義為甲狀腺荷爾蒙放出的異常,治療需要適當的藥物。

本報告以甲狀腺疾病治療為焦點,提供甲狀腺功能降低治療和甲狀腺功能亢進治療區分、2015-2023年期間交易規模變遷的各地區預測、產業結構、供需趨勢、推動&阻礙因素、機會、競爭環境等分析資訊和主要加入企業簡介彙整。

第1章 序

  • 概要
  • 報告相關的說明
  • 市場區隔
  • 調查方法
  • 前提

第2章 摘要整理

  • 甲狀腺疾病治療市場 - 市場簡述
  • 甲狀腺疾病治療的全球市場收益 - 各對象疾病:2014年 (單位:100萬美元)
  • 甲狀腺疾病治療的全球市場收益 - 各藥物分類:2014年 (單位:100萬美元)
  • 甲狀腺疾病治療的全球市場構成比 - 各地區 (% - 金額為基礎)

第3章 產業分析

  • 簡介
  • 流行病學 - 甲狀腺疾病
    • 疾病的背景
    • 風險因素和共生病症
    • 北美的年齡、男女特有病例
    • 歐洲的年齡、男女特有病例
    • 亞太地區的年齡、男女特有病例
    • 其他地區的年齡、男女特有病例
  • 市場動態
    • 市場推動要素
      • 甲狀腺疾病發生數量的增加
      • 在肥胖症、糖尿病、心血管症患者增加上預測的甲狀腺疾病風險的增加伴隨的對症藥物需求
      • 在開發中國家擴大的疾病認識程序
    • 阻礙市場要素
      • 在客戶間要求替代治療聲音高漲
      • 甲狀腺疾病的無症狀性導致大量未確診的人口
    • 市場機會
      • 新興國家的實際成果擴大帶來持續成長機會
  • 法律規範 - 甲狀腺疾病治療的全球市場
  • 現象的影響度分析 - 甲狀腺疾病治療的全球市場
  • 市場向心力分析 - 甲狀腺疾病治療的全球市場
  • 各企業市場佔有率 - 甲狀腺疾病治療的全球市場:2014年 (%)

第4章 市場區隔 - 各對象疾病

  • 簡介
  • 甲狀腺疾病治療的全球市場收益 - 各對象疾病:2013-2023年 (單位:100萬美元)
  • 甲狀腺機能低下症治療的全球市場收益 - 各藥物:2013-2023年 (單位:100萬美元)
    • Levothyroxine的全球市場收益:2013-2023年 (單位:100萬美元)
    • Liothyronine的全球市場收益:2013-2023年 (單位:100萬美元)
  • 甲狀腺功能亢進症治療的全球市場收益 - 各藥物:2013-2023年 (單位:100萬美元)
    • Imidazole的全球市場收益:2013-2023年 (單位:100萬美元)
    • Propacil的全球市場收益:2013-2023年 (單位:100萬美元)

第5章 市場區隔 - 各地區

  • 甲狀腺疾病治療的全球市場收益 - 各地區:2013-2023年 (單位:100萬美元)
  • 北美的甲狀腺疾病治療的全球市場收益 - 各對象疾病:2013-2023年 (單位:100萬美元)
  • 歐洲的甲狀腺疾病治療的全球市場收益 - 各對象疾病:2013-2023年 (單位:100萬美元)
  • 亞太地區的甲狀腺疾病治療的全球市場收益 - 各對象疾病:2013-2023年 (單位:100萬美元)
  • 亞太地區的甲狀腺疾病治療的全球市場收益 - 各國:2013-2023年 (單位:100萬美元)
    • 中國
    • 其他亞太地區各國
  • 中南美的甲狀腺疾病治療的全球市場收益 - 各對象疾病:2013-2023年 (單位:100萬美元)
  • 中南美的甲狀腺疾病治療的全球市場收益 - 各國:2013-2023年 (單位:100萬美元)
    • 巴西
    • 其他中南美各國
  • 中東、非洲的甲狀腺疾病治療的全球市場 - 各對象疾病:2013-2023年 (單位:100萬美元)
  • 其他地區的甲狀腺疾病治療的全球市場:2013-2023年 (單位:100萬美元)

第6章 建議

  • 研究開發活動的擴大
  • 對疾病的認識擴大及促銷宣傳活動的強化
  • 有效並用給藥的甲狀腺藥物治療

第7章 企業簡介

  • Abbott Laboratories
  • AbbVie, Inc.
  • Allergan plc
  • GlaxoSmithKline plc
  • Pfizer, Inc.
  • Lannett Company, Inc.
  • Merck KGaA
  • Mylan N.V.
  • Novartis International AG
  • Sanofi
  • 武田藥品工業株式會社

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Global Thyroid Gland Disorders Treatment Market: Overview

This report on the thyroid gland disorders treatment market analyzes the current and future scenario of the global market. Increasing incidence of thyroid gland disorders. Government regulations and initiatives for increasing awareness about thyroid gland disorders treatment are the major drivers of the global Thyroid Gland Disorders Treatment Market.

The thyroid gland disorders treatment market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on Disorders, and geography. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the market overview section. In addition, the section comprises competitive matrix and company profiles with business overview to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis, by geography and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global thyroid gland disorders treatment market.

Global Thyroid Gland Disorders Treatment Market: Key Segments

Based on Disorders, the market has been segmented into hypothyroidism and hyperthyroidism. The disorders market segments have been analyzed based on available approved treatments for hypothyroidism and hyperthyroidism, cost-effectiveness, and preference for industries. Furthermore, Hypothyroidism is categorized into Levothyroxine and Liothyronine, where hyperthyroidism is categorized into Imidazole and Propacil. The market size and forecast for each of these segments have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year.

Global Thyroid Gland Disorders Treatment Market: Regional Outlook

Geographically, the global thyroid gland disorders treatment market has been categorized into five major regions and the key countries in the respective region: North America (the U.S., Canada), Europe (the U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America) and Middle East & Africa (South Africa, GCC countries, Israel, and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year. The research study also covers the competitive scenario in these regions.

Companies Mentioned in Report

The report also profiles major players in the global thyroid gland disorders treatment market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The major players in the Thyroid Gland Disorders Treatment Market are Merck KGaA, Pfizer, Inc., Takeda Pharmaceutical Company Limited, ALLERGAN, Sanofi S.A., AbbVie Inc., Lannett Company, Inc., Aspen, Novartis AG, Mylan N.V., and Others.

The global thyroid gland disorders treatment market is segmented as given below:

  • Global Thyroid Gland Disorders Treatment Market Revenue, by Disorders, 2015-2025
  • Hypothyroidism
  • Levothyroxine
  • Liothyronine
  • Hyperthyroidism
  • Imidazole
  • Propacil
  • Global Thyroid Gland Disorders Treatment Market Revenue, By Geography, 2015-2025
  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • U.K.
  • Italy
  • France
  • Spain
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • Japan
  • Australia & New Zealand
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • GCC countries
  • South Africa
  • Israel
  • Rest of Middle East & Africa

Table of Contents

1. Preface

  • 1.1. Report Scope and Market Segmentation
  • 1.2. Research Highlights

2. Assumptions and Research Methodology

  • 2.1. Assumptions and Acronyms Used
  • 2.2. Research Methodology

3. Executive Summary

  • 3.1. Global Thyroid Gland Disorders Treatment Market Size (US$ Mn) and Distribution, by Region, 2017 and 2025
  • 3.2. Global Thyroid Gland Disorders Treatment Market: Market Snapshot

4. Market Overview

  • 4.1. Global Thyroid Gland Disorders Treatment Market: Product Overview
  • 4.2. Global Thyroid Gland Disorders Treatment Market: Key Industry Developments

5. Market Dynamics

  • 5.1. Drivers and Restraints Snapshot Analysis
  • 5.2. Drivers
    • 5.2.1. Increasing incidence of thyroid gland disorders
    • 5.2.2. Rise in the number of obese, diabetic, and cardiovascular patients, leading to increased risk of thyroid disorders
    • 5.2.3. Growing number of disease awareness programs in developing regions
    • 5.2.4. Focus on spreading awareness about disorders as well as promotional campaigns
    • 5.2.5. Development of effective combination thyroid disorders drug therapies
  • 5.3. Restraints
    • 5.3.1. Rising customer preference for alternative treatments
    • 5.3.2. Asymptomatic nature of thyroid disorders leading to large pool of undiagnosed patients
  • 5.4. Opportunities
    • 5.4.1. Asymptomatic nature of thyroid disorders leading to large pool of undiagnosed patients
    • 5.4.2. Increase in research and development activities
  • 5.5. Global Thyroid Gland Disorders (Hypothyroidism and Hyperthyroidism) Epidemiology
  • 5.6. Global Thyroid Gland Disorders Treatment Market Revenue Forecast
  • 5.7. Global Thyroid Gland Disorders Treatment Market Outlook

6. Global Thyroid Gland Disorders Treatment Market Analysis, by Disorders

  • 6.1. Introduction
  • 6.2. Key Insights
  • 6.3. Global Thyroid Gland Disorders Treatment Market Analysis, by Disorders
    • 6.3.1. Hypothyroidism
      • 6.3.1.1. Levothyroxine
      • 6.3.1.2. Liothyronine
    • 6.3.2. Hyperthyroidism
      • 6.3.2.1. Imidazole
      • 6.3.2.2. Propacil
  • 6.4. Global Thyroid Gland Disorders Treatment Market Forecast, by Disorders
    • 6.4.1. Hypothyroidism
      • 6.4.1.1. Levothyroxine
      • 6.4.1.2. Liothyronine
    • 6.4.2. Hyperthyroidism
      • 6.4.2.1. Imidazole
      • 6.4.2.2. Propacil
  • 6.5. Global Thyroid Gland Disorders Treatment Market Attractiveness Analysis, by Disorders
    • 6.5.1. Hypothyroidism
    • 6.5.2. Hyperthyroidism

7. Global Thyroid Gland Disorders Treatment Market Analysis, by Region

  • 7.1. Global Thyroid Gland Disorders Treatment Market Forecast, by Region, 2015-2025
    • 7.1.1. North America
    • 7.1.2. Europe
    • 7.1.3. Asia Pacific
    • 7.1.4. Latin America
    • 7.1.5. Middle East & Africa
  • 7.2. Global Thyroid Gland Disorders Treatment Market Value Share Analysis, by Region
  • 7.3. Global Thyroid Gland Disorders Treatment Market Attractiveness Analysis, by Region

8. North America Thyroid Gland Disorders Treatment Market Analysis

  • 8.1. North America Thyroid Gland Disorders Treatment Market Key Findings
  • 8.2. North America Thyroid Gland Disorders Treatment Market Overview
  • 8.3. North America Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorders
    • 8.3.1. Hypothyroidism
      • 8.3.1.1. Levothyroxine
      • 8.3.1.2. Liothyronine
    • 8.3.2. Hyperthyroidism
      • 8.3.2.1. Imidazole
      • 8.3.2.2. Propacil
  • 8.4. North America Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorders
    • 8.4.1. Hypothyroidism
    • 8.4.2. Hyperthyroidism
  • 8.5. North America Thyroid Gland Disorders Treatment Market Forecast, by Country
    • 8.5.1. U.S.
    • 8.5.2. Canada
  • 8.6. North America Thyroid Gland Disorders Treatment Market Attractiveness Analysis, by Disorders
    • 8.6.1. Hypothyroidism
    • 8.6.2. Hyperthyroidism

9. Europe Thyroid Gland Disorders Treatment Market Analysis

  • 9.1. Europe Thyroid Gland Disorders Treatment Market Key Findings
  • 9.2. Europe Thyroid Gland Disorders Treatment Market Overview
  • 9.3. Europe Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorders
    • 9.3.1. Hypothyroidism
      • 9.3.1.1. Levothyroxine
      • 9.3.1.2. Liothyronine
    • 9.3.2. Hyperthyroidism
      • 9.3.2.1. Imidazole
      • 9.3.2.2. Propacil
  • 9.4. Europe Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorders
    • 9.4.1. Hypothyroidism
    • 9.4.2. Hyperthyroidism
  • 9.5. Europe Thyroid Gland Disorders Treatment Market Forecast, by Country
    • 9.5.1. Germany
    • 9.5.2. U.K.
    • 9.5.3. France
    • 9.5.4. Italy
    • 9.5.5. Spain
    • 9.5.6. Rest of Europe
  • 9.6. Europe Thyroid Gland Disorders Treatment Market Attractiveness Analysis, by Disorders
    • 9.6.1. Hypothyroidism
    • 9.6.2. Hyperthyroidism

10. Asia Pacific Thyroid Gland Disorders Treatment Market Analysis

  • 10.1. Asia Pacific Thyroid Gland Disorders Treatment Market Key Findings
  • 10.2. Asia Pacific Thyroid Gland Disorders Treatment Market Overview
  • 10.3. Asia Pacific Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorders
    • 10.3.1. Hypothyroidism
      • 10.3.1.1. Levothyroxine
      • 10.3.1.2. Liothyronine
    • 10.3.2. Hyperthyroidism
      • 10.3.2.1. Imidazole
      • 10.3.2.2. Propacil
  • 10.4. Asia Pacific Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorders
    • 10.4.1. Hypothyroidism
    • 10.4.2. Hyperthyroidism
  • 10.5. Asia Pacific Thyroid Gland Disorders Treatment Market Forecast, by Country
    • 10.5.1. China
    • 10.5.2. India
    • 10.5.3. Japan
    • 10.5.4. Australia & New Zealand
    • 10.5.5. Rest of Asia Pacific
  • 10.6. Asia Pacific Thyroid Gland Disorders Treatment Market Attractiveness Analysis, by Disorders
    • 10.6.1. Hypothyroidism
    • 10.6.2. Hyperthyroidism

11. Latin America Thyroid Gland Disorders Treatment Market Analysis

  • 11.1. Latin America Thyroid Gland Disorders Treatment Market Key Findings
  • 11.2. Latin America Thyroid Gland Disorders Treatment Market Overview
  • 11.3. Latin America Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorders
    • 11.3.1. Hypothyroidism
      • 11.3.1.1. Levothyroxine
      • 11.3.1.2. Liothyronine
    • 11.3.2. Hyperthyroidism
      • 11.3.2.1. Imidazole
      • 11.3.2.2. Propacil
  • 11.4. Latin America Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorders
    • 11.4.1. Hypothyroidism
    • 11.4.2. Hyperthyroidism
  • 11.5. Latin America Thyroid Gland Disorders Treatment Market Forecast, by Country
    • 11.5.1. Brazil
    • 11.5.2. Mexico
    • 11.5.3. Rest of Latin America
  • 11.6. Latin America Thyroid Gland Disorders Treatment Market Attractiveness Analysis, by Disorders
    • 11.6.1. Hypothyroidism
    • 11.6.2. Hyperthyroidism

12. Middle East & Africa Thyroid Gland Disorders Treatment Market Analysis

  • 12.1. Middle East & Africa Thyroid Gland Disorders Treatment Market Key Findings
  • 12.2. Middle East & Africa Thyroid Gland Disorders Treatment Market Overview
  • 12.3. Middle East & Africa Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorders
    • 12.3.1. Hypothyroidism
      • 12.3.1.1. Levothyroxine
      • 12.3.1.2. Liothyronine
    • 12.3.2. Hyperthyroidism
      • 12.3.2.1. Imidazole
      • 12.3.2.2. Propacil
  • 12.4. Middle East & Africa Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorders
    • 12.4.1. Hypothyroidism
    • 12.4.2. Hyperthyroidism
  • 12.5. Middle East & Africa Thyroid Gland Disorders Treatment Market Forecast, by Country
    • 12.5.1. GCC Countries
    • 12.5.2. South Africa
    • 12.5.3. Israel
    • 12.5.4. Rest of Middle East & Africa
  • 12.6. Middle East & Africa Thyroid Gland Disorders Treatment Market Attractiveness Analysis, by Disorders
    • 12.6.1. Hypothyroidism
    • 12.6.2. Hyperthyroidism

13. Competition Landscape

  • 13.1. Global Thyroid Gland Disorders Treatment Market Share Analysis, by Company (2016)
  • 13.2. Company Profiles
    • 13.2.1. Merck KGaA
      • 13.2.1.1. Overview (HQ, Employee Strength, Business Segments)
      • 13.2.1.2. Financials
      • 13.2.1.3. Recent Developments
      • 13.2.1.4. Strategy
    • 13.2.2. Pfizer, Inc.
      • 13.2.2.1. Overview (HQ, Employee Strength, Business Segments)
      • 13.2.2.2. Financials
      • 13.2.2.3. Recent Developments
      • 13.2.2.4. Strategy
    • 13.2.3. Takeda Pharmaceutical Company Limited
      • 13.2.3.1. Overview (HQ, Employee Strength, Business Segments)
      • 13.2.3.2. Financials
      • 13.2.3.3. Recent Developments
      • 13.2.3.4. Strategy
    • 13.2.4. ALLERGAN
      • 13.2.4.1. Overview (HQ, Employee Strength, Business Segments)
      • 13.2.4.2. Financials
      • 13.2.4.3. Recent Developments
      • 13.2.4.4. Strategy
    • 13.2.5. Sanofi S.A.
      • 13.2.5.1. Overview (HQ, Employee Strength, Business Segments)
      • 13.2.5.2. Financials
      • 13.2.5.3. Recent Developments
      • 13.2.5.4. Strategy
    • 13.2.6. AbbVie Inc.
      • 13.2.6.1. Overview (HQ, Employee Strength, Business Segments)
      • 13.2.6.2. Financials
      • 13.2.6.3. Recent Developments
      • 13.2.6.4. Strategy
    • 13.2.7. Lannett Company, Inc.
      • 13.2.7.1. Overview (HQ, Employee Strength, Business Segments)
      • 13.2.7.2. Financials
      • 13.2.7.3. Recent Developments
      • 13.2.7.4. Strategy
    • 13.2.8. Aspen
      • 13.2.8.1. Overview (HQ, Employee Strength, Business Segments)
      • 13.2.8.2. Financials
      • 13.2.8.3. Recent Developments
      • 13.2.8.4. Strategy
    • 13.2.9. Novartis AG
      • 13.2.9.1. Overview (HQ, Employee Strength, Business Segments)
      • 13.2.9.2. Financials
      • 13.2.9.3. Recent Developments
      • 13.2.9.4. Strategy
    • 13.2.10. Mylan N.V.
      • 13.2.10.1. Overview (HQ, Employee Strength, Business Segments)
      • 13.2.10.2. Financials
      • 13.2.10.3. Recent Developments
      • 13.2.10.4. Strategy

List of Tables

  • TABLE 1 Global Thyroid Gland Disorders Treatment Market Value (US$ Mn) Forecast, by Disorder, 2015-2025
  • TABLE 2 Global Thyroid Gland Disorders Treatment Market Value (US$ Mn) Forecast, by Hypothyroidism Drug Class,
  • TABLE 3 Global Thyroid Gland Disorders Treatment Market Value (US$ Mn) Forecast, by Hyperthyroidism Drug Class,
  • TABLE 4 Global Thyroid Gland Disorders Treatment Market Size (US$ Mn) Forecast, by Region, 2015-2025
  • TABLE 5 North America Thyroid Gland Disorders Treatment Market Value (US$ Mn) Forecast, by Disorders, 2015-2025
  • TABLE 6 North America Thyroid Gland Disorders Treatment Market Value (US$ Mn) Forecast, by Hypothyroidism Drug Class, 2015-2025
  • TABLE 7 North America Thyroid Gland Disorders Treatment Market Value (US$ Mn) Forecast, by Hyperthyroidism Drug Class, 2015-2025
  • TABLE 8 North America Thyroid Gland Disorders Treatment Market Value (US$ Mn) Forecast, by Country, 2015-2025
  • TABLE 9 Europe Thyroid Gland Disorders Treatment Market Value (US$ Mn) Forecast, by Disorder, 2015-2025
  • TABLE 10 Europe Thyroid Gland Disorders Treatment Market Value (US$ Mn) Forecast, by Hypothyroidism Drug Class, 2015-2025
  • TABLE 11 Europe Thyroid Gland Disorders Treatment Market Value (US$ Mn) Forecast, by Hyperthyroidism Drug Class, 2015-2025
  • TABLE 12 Europe Thyroid Gland Disorders Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2015-2025
  • TABLE 13 Asia Pacific Thyroid Gland Disorders Treatment Market Value (US$ Mn) Forecast, by Disorder, 2015-2025
  • TABLE 14 Asia Pacific Thyroid Gland Disorders Treatment Market Value (US$ Mn) Forecast, by Hypothyroidism Drug Class, 2015-2025
  • TABLE 15 Asia Pacific Thyroid Gland Disorders Treatment Market Value (US$ Mn) Forecast, by Hyperthyroidism Drug Class, 2015-2025
  • TABLE 16 Asia Pacific Thyroid Gland Disorders Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2015-2025
  • TABLE 17 Latin America Thyroid Gland Disorders Treatment Market Value (US$ Mn) Forecast, by Disorder, 2015-2025
  • TABLE 18 Latin America Thyroid Gland Disorders Treatment Market Value (US$ Mn) Forecast, by Hypothyroidism Drug Class, 2015-2025
  • TABLE 19 Latin America Thyroid Gland Disorders Treatment Market Value (US$ Mn) Forecast, by Hyperthyroidism Drug Class, 2015-2025
  • TABLE 20 Latin America Thyroid Gland Disorders Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2015-2025
  • TABLE 21 Middle East & Africa Thyroid Gland Disorders Treatment Market Value (US$ Mn) Forecast, by Disorders, 2015-2025
  • TABLE 22 Middle East & Africa Thyroid Gland Disorders Treatment Market Value (US$ Mn) Forecast, by Hypothyroidism Drug Class, 2015-2025
  • TABLE 23 Middle East & Africa Thyroid Gland Disorders Treatment Market Value (US$ Mn) Forecast, by Hyperthyroidism Drug Class, 2015-2025
  • TABLE 24 Middle East & Africa Thyroid Gland Disorders Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2015-202

List of Figures

  • FIG. 1 Global Thyroid Gland Disorders Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2025
  • FIG. 2 Global Thyroid Gland Disorders Market Value Share, by Disorders (2016)
  • FIG. 3 Global Thyroid Gland Disorders Market Value Share, by Hypothyroidism Drug Class (2016)
  • FIG. 4 Global Thyroid Gland Disorders Market Value Share, by Region (2016)
  • FIG. 5 Global Thyroid Gland Disorders Market Value Share, by Hyperthyroidism Drug Class (2016)
  • FIG. 6 Global Thyroid Gland Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth, by Hypothyroidism, 2015-2025
  • FIG. 7 Global Thyroid Gland Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth, by Hyperthyroidism, 2015-2025
  • FIG. 8 Global Thyroid Gland Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth, by Levothyroxine, 2015-2025
  • FIG. 9 Global Thyroid Gland Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth, by Liothyronine, 2015-2025
  • FIG. 10 Global Thyroid Gland Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth, by Imidazole, 2015-2025
  • FIG. 11 Global Thyroid Gland Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth, by Propacil, 2015-2025
  • FIG. 12 Global Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorder, 2016 and 2025
  • FIG. 13 Global Thyroid Gland Disorders Treatment Market Value Share Analysis, by Hypothyroidism Drug Class, 2016 and 2025
  • FIG. 14 Global Thyroid Gland Disorders Treatment Market Value Share Analysis, by Hyperthyroidism Drug Class, 2016 and 2025
  • FIG. 15 Global Thyroid Gland Disorders Treatment Market Attractiveness Analysis, by Disorder
  • FIG. 16 Global Thyroid Gland Disorders Treatment Market Value Share Analysis, by Region, 2016 and 2025
  • FIG. 17 Global Thyroid Gland Disorders Treatment Market Attractiveness Analysis, by Region
  • FIG. 18 North America Thyroid Gland Disorders Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth, 2015-2025
  • FIG. 19 North America Market Attractiveness Analysis, by Country
  • FIG. 20 North America Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorders, 2016 and 2025
  • FIG. 21 North America Thyroid Gland Disorders Treatment Market Value Share Analysis, by Hypothyroidism Drug Class, 2016 and 2025
  • FIG. 22 North America Thyroid Gland Disorders Treatment Market Value Share Analysis, by Hyperthyroidism Drug Class, 2016 and 2025
  • FIG. 23 North America Thyroid Gland Disorders Treatment Market Value Share Analysis, by Country, 2016 and 2025
  • FIG. 24 North America Thyroid Gland Disorders Treatment Market Attractiveness Analysis, by Disorder
  • FIG. 25 Europe Thyroid Gland Disorders Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth, 2015-2025
  • FIG. 26 Europe Market Attractiveness Analysis, by Country
  • FIG. 27 Europe Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorder, 2016 and 2025
  • FIG. 28 Europe Thyroid Gland Disorders Treatment Market Value Share Analysis, by Hypothyroidism Drug Class, 2016 and 2025
  • FIG. 29 Europe Thyroid Gland Disorders Treatment Market Value Share Analysis, by Hyperthyroidism Drug Class, 2016 and 2025
  • FIG. 30 Europe Thyroid Gland Disorders Treatment Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
  • FIG. 31 Europe Thyroid Gland Disorders Treatment Market Attractiveness Analysis, by Disorder, 2015-2025
  • FIG. 32 Asia Pacific Thyroid Gland Disorders Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth, 2015-2025
  • FIG. 33 Asia Pacific Market Attractiveness Analysis, by Country/Sub-region
  • FIG. 34 Asia Pacific Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorder, 2016 and 2025
  • FIG. 35 Asia Pacific Thyroid Gland Disorders Treatment Market Value Share Analysis, by Hypothyroidism Drug Class, 2016 and 2025
  • FIG. 36 Asia Pacific Thyroid Gland Disorders Treatment Market Value Share Analysis, by Hyperthyroidism Drug Class, 2016 and 2025
  • FIG. 37 Asia Pacific Thyroid Gland Disorders Treatment Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
  • FIG. 38 Asia Pacific Thyroid Gland Disorders Treatment Market Attractiveness Analysis, by Disorders
  • FIG. 39 Latin America Thyroid Gland Disorders Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth, 2015-2025
  • FIG. 40 Latin America Market Attractiveness Analysis, by Country/Sub-region
  • FIG. 41 Latin America Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorder, 2016 and 2025
  • FIG. 42 Latin America Thyroid Gland Disorders Treatment Market Value Share Analysis, by Hypothyroidism Drug Class, 2016 and 2025
  • FIG. 43 Latin America Thyroid Gland Disorders Treatment Market Value Share Analysis, by Hyperthyroidism Drug Class, 2016 and 2025
  • FIG. 44 Latin America Thyroid Gland Disorders Treatment Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
  • FIG. 45 Latin America Thyroid Gland Disorders Treatment Market Attractiveness Analysis, by Disorder
  • FIG. 46 Middle East & Africa Thyroid Gland Disorders Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth, 2015-2025
  • FIG. 47 Middle East & Africa Market Attractiveness Analysis, by Country/Sub-region
  • FIG. 48 Middle East & Africa Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorder, 2016 and 2025
  • FIG. 49 Middle East & Africa Thyroid Gland Disorders Treatment Market Value Share Analysis, by Hypothyroidism Drug Class, 2016 and 2025
  • FIG. 50 Middle East & Africa Thyroid Gland Disorders Treatment Market Value Share Analysis, by Hyperthyroidism Drug Class, 2016 and 2025
  • FIG. 51 Middle East & Africa Thyroid Gland Disorders Treatment Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
  • FIG. 52 Middle East & Africa Thyroid Gland Disorders Treatment Market Attractiveness Analysis, by Disorder
  • FIG. 53 Global Thyroid Gland Disorders Treatment Market Company Share Analysis (2016)
  • FIG. 54 Merck KGaA Revenue (US$ Bn) & Y-o-Y Growth (%), 2013-2016
  • FIG. 55 Merck KGaA Breakdown of Net Sales, by Region, 2016
  • FIG. 56 Breakdown of Net Sales, by Business Segment, 2016
  • FIG. 57 Merck KGaA R&D Expenses (US$ Bn) & Y-o-Y Growth (%), 2014-2016
  • FIG. 58 Pfizer, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2013-2016
  • FIG. 59 Pfizer, Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2013-2016
  • FIG. 60 Pfizer, Inc. Breakdown of Net Sales, by Region, 2016
  • FIG. 61 Pfizer, Inc. Sales & Marketing Expenses (US$ Mn) and Y-o-Y Growth (%), 2013-2016
  • FIG. 62 Takeda Pharmaceutical Company Limited Revenue (US$ Mn) and Y-o-Y Growth (%), 2013-2016
  • FIG. 63 Takeda Pharmaceutical Company Limited R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2013-2016
  • FIG. 64 Takeda Pharmaceutical Company Limited Breakdown of Net Sales, by Region
  • FIG. 65 Takeda Pharmaceutical Company Limited Sales & Marketing Expenses (US$ Mn) and Y-o-Y Growth (%), 2013-2016
  • FIG. 66 ALLERGAN Revenue (US$ Mn) and Y-o-Y Growth (%), 2013-2016
  • FIG. 67 ALLERGAN R&D Spending and Sales & Marketing Expenses - Company Level, 2015-2016
  • FIG. 68 ALLERGAN Breakdown of Net Sales, by Operating Segment, 2016
  • FIG. 69 Sanofi S.A. Revenue (US$ Mn) and Y-o-Y Growth (%), 2013-2016
  • FIG. 70 Sanofi S.A. R&D Spending and Sales & Marketing Expenses - Company Level, 2014-2016
  • FIG. 71 Sanofi S.A. Breakdown of Net Sales, by Region, 2016
  • FIG. 72 Sanofi S.A. Breakdown of Net Sales, by Business Segment, 2016
  • FIG. 73 AbbVie Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2013-2016
  • FIG. 74 AbbVie Inc. R&D Expenses and Sales & Marketing Expenses- Company Level, 2015-2016
  • FIG. 75 AbbVie Inc. Breakdown of Net Sales, by Region, 2016
  • FIG. 76 AbbVie Inc. Breakdown of Net Sales, by Major Brands, 2016
  • FIG. 77 Lannett Company, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2013-2016
  • FIG. 78 Lannett Company, Inc. Breakdown of Net Sales, by Business Segments, 2016
  • FIG. 79 Lannett Company, Inc. Breakdown of Net Sales, by Customer Distribution Channel, 2016
  • FIG. 80 Aspen Revenue (US$ Mn) & Y-o-Y Growth (%), 2013-2016
  • FIG. 81 Aspen R&D Expenses and Sales & Marketing Expenses(%) - Company Level, 2015-2016
  • FIG. 82 Aspen Breakdown of Net Sales, By Region 2016
  • FIG. 83 Aspen Breakdown of Net Sales, (Overall Company Level), 2016
  • FIG. 84 Novartis AG Revenue (US$ Mn) & Y-o-Y Growth (%), 2013-2016
  • FIG. 85 Novartis AG R&D Expenses and Sales & Marketing Expenses(%) - Company Level, 2015-2016
  • FIG. 86 Novartis AG Breakdown of Net Sales, By Region 2016
  • FIG. 87 Novartis AG Breakdown of Net Sales, Business Segments, 2016
  • FIG. 88 Mylan N.V. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013-2016
  • FIG. 89 Mylan N.V. R&D Expenses and Sales & Marketing Expenses(%) - Company Level, 2015-2016
  • FIG. 90 Mylan N.V. Breakdown of Net Sales, By Region 2016
  • FIG. 91 Mylan N.V. Breakdown of Net Sales, Business Segments, 2016
Back to Top